Top Biotech Gainers: APLM Climbs 22%; IOVA, RCEL On Watch; MANE Gains On Hair Loss Data

Biotech stocks rose Wednesday. Apollomics (APLM) jumped 22% after Nasdaq closed its MVLS compliance issue. Iovance (IOVA) gained 21% ahead of Q2 results; AVITA Medical (RCEL) rose 18% before Aug. 6 earnings; Annexon (ANNX) climbed 17% ahead of ARCHER II updates. Veradermics (MANE) gained 12% on Phase 2 hair-loss topline results.

Original reporting
Published Jul 16, 2026, 5:45 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 16, 2026, 5:50 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefMarket movers
Primary signal
$APLM
Bullish
medium confidence
Mentioned
$APLM · $IOVA · $RCEL · $ANNX · $ANL · $MANE
Relevance
7/10
AlphAI data visualization · based on rttnews.com
Decision brief

The 30-second read

$APLMBullishMed
01

Why it matters

The most tradable fundamental catalyst in the text is MANE’s positive Phase 2 topline with specific Month 2 and Month 6 response metrics. Several other names appear to be trading on event proximity (earnings or conference) rather than new operational data.

02

Market read

Traders can use the article’s concrete catalysts and dates to manage event risk around earnings (IOVA, RCEL) and conference/pivotal-readout timelines (ANNX), with MANE offering the clearest new efficacy datapoints.

03

What to watch

For IOVA, the iCTC maintenance capacity constraint could cap upside even if revenue expectations are met; for MANE, open-label Phase 2 design may inflate perceived efficacy versus controlled trials.

Relevance 7/10Novelty 6/10Timing: pre-market/Wednesday session into upcoming catalysts (Aug 6 RCEL results, early-Aug IOVA results, July 18 ANNX ASRS)

Background

This is a biotech “movers” roundup highlighting several stocks with large single-day gains tied to compliance updates, pre-earnings positioning, conference timing, insider ownership filings, and one positive hair-loss trial topline.

Company-level read

Ticker impact

$APLMBullishMedium confidence
Context

Apollomics shares jumped over 20% after Nasdaq closed its MVLS compliance matter on July 8, 2026.

Expected impact

Choppy but supportive for several sessions; fades if no new clinical catalyst appears.

Evidence & confidence

The catalyst is regulatory/compliance closure, not trial data, so it can drive a short squeeze and sentiment lift, but durability is uncertain.

$IOVABullishMedium confidence
Context

Iovance rallied more than 20% with no specific news, ahead of Q2 2026 results in early August.

Expected impact

Potential continuation into the print, but volatility likely around guidance and iCTC maintenance effects.

Evidence & confidence

The article provides concrete expectations for Q2 revenue and notes capacity constraints, which can become the key debate for the upcoming report.

$RCELBullishLow confidence
Context

AVITA Medical gained about 18% ahead of Q2 2026 results after the close on August 6, 2026.

Expected impact

Elevated volatility into August 6; direction depends on whether revenue and burn-rate trends beat expectations.

Evidence & confidence

The article does not provide new guidance or datapoints beyond historical Q1/Q2 2025 figures, so the edge is limited.

$ANNXBullishLow confidence
Context

Annexon jumped more than 17% ahead of an ASRS July 18 presentation for ARCHER II baseline factors, with Phase 3 topline expected in Q4 2026.

Expected impact

Likely strength into July 18, then mean reversion unless the presentation contains incremental signals.

Evidence & confidence

Baseline characteristics are supportive but not the pivotal topline; the article does not disclose new efficacy outcomes.

$ANLBullishLow confidence
Context

Adlai Nortye rose about 15% after a Form 3 showed director and 10% holder Roger Sawhney’s initial beneficial ownership.

Expected impact

Limited upside follow-through; more likely a short-lived sentiment effect.

Evidence & confidence

The article is an ownership filing, not a change in business outlook or trial results.

$MANEBullishMedium confidence
Context

Veradermics surged over 12% on positive topline Phase 2 results for VDPHL01 in female pattern hair loss, including Month 6 response rates.

Expected impact

Potential continuation while traders extrapolate into Study 306 and Phase 2/3 readouts; pullbacks possible on valuation and durability questions.

Evidence & confidence

The article includes specific topline metrics (coverage improvements by Month 2 and improved/much improved rates by Month 6), which can drive re-rating and positioning.

Market effects

Reinforces that biotech traders are rewarding near-term de-risking (Nasdaq compliance closure) and concrete clinical topline metrics, while conference and pre-earnings positioning can drive outsized intraday moves.

Primarily US-listed biotech sentiment; no explicit cross-region macro linkage in the text.

Limited global spillover; catalysts are company-specific and US regulatory/conference driven.

Counterpoint

Some gains (IOVA, RCEL, ANNX) are not tied to new efficacy or guidance in the article, so momentum could reverse quickly if the market already priced the upcoming catalysts.

Key entities

  • Apollomics Inc.

    Nasdaq MVLS compliance matter closed; shares surged on the de-risking headline.

  • Iovance Biotherapeutics Inc.

    Amtagvi TIL therapy; stock jumped ahead of Q2 results and amid manufacturing-capacity discussion.

  • AVITA Medical, Inc.

    RECELL acute wound care; stock rose ahead of Q2 results on Aug 6.

  • Annexon Inc.

    ARCHER II Phase 3 program; stock rose ahead of ASRS July 18 baseline presentation.

  • Adlai Nortye

    Form 3 insider ownership disclosure by a director and 10% holder.

Related articles

$SLSHighAI 8/10

SLS, IBRX And IOVA Join Merck And Lilly On BlackRock’s Q3 Buy List — A Vanguard Unit Adds All Of Them Too

BlackRock and a Vanguard unit added SLS, IBRX, IOVA, MRK, and LLY to their Q3 buy lists. Lilly reported strong sales from diabetes, obesity, and cancer drugs. Sellas (SLS) awaits Phase 3 trial results for its AML treatment. ImmunityBio (IBRX) plans expanded FDA approval for Anktiva. Iovance (IOVA) saw 77% YoY sales growth for Amtagvi and is testing it with Merck's (MRK) Keytruda. Retail sentiment varies across stocks.

$ANNXHigh

Wells Fargo Names Top Pick in Biotechnology Sector

Wells Fargo named Annexon, Inc. its top biotech pick, maintaining an Overweight rating and $27.00 price target. The firm cited the company's ARCHER II trial for vonaprument in generalized myasthenia gravis (GA) as a key catalyst, with a 55% success probability. Annexon has near-term catalysts, including a Q4 2026 data readout and a BLA submission. The company has $213M in cash and a $200M credit facility. Shares are down 16% YTD, underperforming the SPDR S&P Biotech ETF's 29% gain.

$MANEHighAI 9/10

Veradermics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress

Veradermics, Inc (MANE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Veradermics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress Positive topline results from Phase 3 Study ‘304’ and positive 12-month data from Phase 2/3 Study ‘302’ position VDPHL01 to potentially become the first ora